Condition: Breast Cancer · Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
This is a multi-center, open-lable, prospective, randomized phase III clinical trial to investigate the efficacy and safety of adjuvant ribociclib combined with aromatase inhibitor in hormone receptor-positive, HER2-negative early breast cancer with residual disease after neoadjuvant chemotherapy
This description comes directly from the study's public registry record.
Chang Gong, Professor · 86+13925089353 · gchang@mail.sysu.edu.cn
Always discuss trial participation with your own doctor first.
| Affiliated Hospital of Guangdong Medical University | Zhanjiang, Guangdong, China | Recruiting |
| Sun Yat-sen Memorial Hospital | Guangzhou, China | Recruiting |
| the First Affiliated Hospital of Guangzhou Medical University | Guangzhou, China | Recruiting |
| Shantou Central Hospital | Shantou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07400523